Company Sector
1 company tagged with TCR-T Therapy.
TCR-T Therapy includes companies engineering T-cell receptors to recognize specific antigens presented by tumor or diseased cells. It is a specialized cell-therapy category with particular relevance in solid tumors and antigen-defined precision immuno-oncology.
ADAP
Adaptimmune Therapeutics plc is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
